ReviewJournal of clinical medicine2019
Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis.ESC heart failure · 2023Pooled it
- The Genetics of Iron Metabolism on Biochemical and Hematological Phenotypes of Heart Failure.International journal of molecular sciences · 2026Article
- Invasive haemodynamic validation of an artificial intelligence echocardiographic tool for detecting heart failure with preserved ejection fraction.ESC heart failure · 2026Article
- Interpretation of cardiac magnetic resonance imaging of left ventricular hypertrophy: a practical guide.Polish journal of radiology · 2026Review
- Sex Differences in 90-Day Readmission and Mortality Trends in Heart Failure With Preserved Ejection Fraction: Insights From the National Readmissions Database.International journal of heart failure · 2025Article
- Ventricular-Arterial Coupling in Heart Failure with Preserved Ejection Fraction: A Bibliometric Review and Clinical Implications.Cardiac failure review · 2025Review
- Comparison of the effects of metformin and empagliflozin on cardiac function in heart failure with preserved ejection fraction mice.Frontiers in cardiovascular medicine · 2025Article
- Epigenetic regulation of sex dimorphism in cardiovascular health.Canadian journal of physiology and pharmacology · 2024Review
- Differential Effect of Sex on Mortality According to Age in Heart Failure.Journal of the American Heart Association · 2024Article
- Identifying sex similarities and differences in structure and function of the sinoatrial node in the mouse heart.Frontiers in medicine · 2024Article
- Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery.Acta pharmacologica Sinica · 2024Review
- Acute Decompensated Heart Failure in the Elderly: An Observational Study in a Regional Victorian Hospital.Cureus · 2024Article
- Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2023Review
- Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes.Nature reviews. Cardiology · 2023Review
- Evaluation of large animal models for preclinical studies of heart failure with preserved ejection fraction using clinical score systems.Frontiers in cardiovascular medicine · 2023Review
- Heart-brain interactions in cardiac and brain diseases: why sex matters.European heart journal · 2022Review
- Sex differences in heart mitochondria regulate diastolic dysfunction.Nature communications · 2022Article
- New antidiabetic therapy and HFpEF: light at the end of tunnel?Heart failure reviews · 2022Review
- Female Health Across the Tree of Life: Insights at the Intersection of Women's Health, One Health and Planetary Health.PNAS nexus · 2022Article
- Cystic fibrosis transmembrane regulator correction attenuates heart failure-induced lung inflammation.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents the most frequent form of heart failure in women, with almost two-fold higher prevalence than in men. Studies have revealed sex-specific HFpEF pathophysiology, and suggested the possibility of a sex-specific therapeutic approach in these patients. Some cardiovascular risk factors, such as arterial hypertension, obesity, diabetes mellitus, coronary artery disease, atrial fibrillation, and race, show specific features that might be responsible for the development of HFpEF in women. These risk factors are related to specific cardiovascular changes-left ventricular diastolic dysfunction and hypertrophy, ventricular-vascular coupling, and impaired functional capacity-that are related to specific cardiac phenotype and HFpEF development. However, there is no agreement regarding outcomes in women with HFpEF. For HFpEF, most studies have found higher hospitalization rates for women than for men. Mortality rates are usually not different. Pharmacological treatment in HFpEF is challenging, along with many unresolved issues and questions raised. Available data on medical therapy in patients with HFpEF show no difference in outcomes between the sexes. Further investigations are necessary to better understand the pathophysiology and mechanisms of HFpEF, as well as to improve and eventually develop sex-specific therapy for HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.